Northwestern Mutual Wealth Management Co. Grows Stake in Stryker Corporation $SYK

Northwestern Mutual Wealth Management Co. raised its position in shares of Stryker Corporation (NYSE:SYK) by 4.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,200 shares of the medical technology company’s stock after purchasing an additional 2,057 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Stryker were worth $14,231,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Rakuten Investment Management Inc. bought a new position in Stryker in the 2nd quarter valued at $18,646,000. Swedbank AB boosted its holdings in shares of Stryker by 6.6% in the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after purchasing an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in Stryker by 31.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after acquiring an additional 6,367 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. Finally, Rathbones Group PLC boosted its position in Stryker by 647.9% during the fourth quarter. Rathbones Group PLC now owns 219,265 shares of the medical technology company’s stock valued at $77,065,000 after buying an additional 189,948 shares during the period. Institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Citizens Jmp cut their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a report on Monday, August 3rd. JPMorgan Chase & Co. cut their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Leerink Partners cut their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Finally, Truist Financial raised their price objective on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Director Mary Brainerd purchased additional Stryker shares on September 2, increasing her personal stake. Insider buying can signal confidence in the company’s valuation and outlook, although the purchase alone is unlikely to materially change earnings expectations. Stryker Insider Makes Bold New Move With Fresh Share Purchase
• Positive Sentiment: Stryker received FDA De Novo authorization for SportSuite Vision, its surgical application for Apple Vision Pro, and completed the first reported hip arthroscopy using the system. The technology could strengthen Stryker’s digital-surgery and orthopedic innovation offerings, though commercial adoption remains to be demonstrated. Stryker introduces FDA-authorized surgical application for Apple Vision Pro
• Positive Sentiment: Stryker agreed to acquire ZuriMED, adding the FiberLocker System and expanding its shoulder-care and rotator-cuff portfolio. The deal could broaden Stryker’s orthopedic product lineup and growth opportunities. Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
• Neutral Sentiment: Analysts remain broadly optimistic about Stryker’s longer-term prospects even as the shares have underperformed the broader market. The company’s latest reported quarter exceeded earnings expectations, but its valuation remains relatively elevated, which can increase sensitivity to growth concerns. Is Stryker Stock Underperforming the Nasdaq?
• Negative Sentiment: The recent underperformance suggests investors may be focused more on valuation, execution, and market-wide factors than on the new product announcements. The ZuriMED transaction also introduces integration and spending risks, with financial terms and its near-term earnings contribution not specified in the available reports.

Stryker Stock Performance

Shares of NYSE SYK opened at $312.10 on Thursday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $119.71 billion, a price-to-earnings ratio of 32.34, a price-to-earnings-growth ratio of 1.99 and a beta of 0.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The firm has a 50 day moving average of $329.60 and a 200 day moving average of $330.33.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio is 36.48%.

Insiders Place Their Bets

In other Stryker news, insider Dylan Bram Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.